Navigation Links
Rigel Provides Pipeline Update
Date:10/24/2013

lan to start the studies early next year," said James M. Gower, chairman and chief executive officer of Rigel.  He also said, "Unfortunately, discoid lupus is a difficult indication and R333 didn't provide the benefit we had hoped. However, this frees up resources to focus on our ITP and dry eye programs." 

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The company currently has five product candidates in development: fostamatinib, an oral SYK inhibitor for ITP that is expected to commence Phase 3 clinical trials in the first half of 2014; R348, a topical JAK/SYK inhibitor for dry eye in Phase 2 clinical trials; R118, an AMPK activator entering Phase 1 in early 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

This press release contains "forward-looking" statements, including, without limitation, statements related to development plans and results, including development plans and timing for fostamatinib for ITP.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "may," "expect," and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel to Present at Stifel Healthcare Conference
2. Rigel To Focus On ITP, DLE And Dry Eye
3. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
4. Rigel Announces Second Quarter 2013 Financial Results
5. Rigel Will Resume Responsibility for Fostamatinib Program
6. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
7. Rigel Announces First Quarter 2013 Financial Results
8. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel to Present at BIO CEO & Investor Conference
11. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Inc. (Nasdaq: BNVI ) announced today that it will ... 2009 ended September 30, 2009 on Thursday, November 5, 2009. ... to review the financial results on Thursday, November 5, 2009 ... call by dialing (800) 860-2442 or (412) 858-4600, or can ...
... October 29 Amsterdam Molecular,Therapeutics (AMT) and Progenika Biopharma ... and commercialization agreement for,LPLchip(TM), a diagnostic tool to rapidly ... AMT has developed Glybera(R) as,a gene therapy for patients ... June of this year AMT announced new clinical data ...
Cached Medicine Technology:AMT Starts Development LPLChip(TM) With Progenika 2AMT Starts Development LPLChip(TM) With Progenika 3
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... Steven Reinberg HealthDay ... New guidelines from the American Diabetes Association (ADA) call for ... with diabetes to help prevent heart disease. These new ... of Cardiology and American Heart Association, which also recommend giving ... heart disease, including people with diabetes. "We agree that ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... ATLANTA, Sept. 23 The Hospital of Central Connecticut (THOCC), ... IM Practice Manager to automate, organize and increase quality of ... physicians at THOCC will be using IM,s handheld and Internet-based solution, ... users, making it the most widely used electronic charge capture system ...
... , SALT LAKE CITY, Sept. 23 Dynatronics Corporation ... quarter and year ended June 30, 2009 during the morning of Friday, ... its third consecutive quarter of profitability. , , Dynatronics ... p.m. ET to discuss its results for the quarter and year periods. ...
... , , ROCHESTER, N.Y., Sept. 23 ... R. Kerry Clark and Robert J. Palmisano have joined its board ... outstanding business leaders with broad and relevant experience," said Gerald M. ... these help us become better positioned for long-term growth. We welcome ...
... Foundation recently received a $1 million planned-gift donation ... radiology fellows to pursue this medical profession. SIR ... of interventional radiology by specializing in developing investigators ... research. "This enormously generous gift supports the ...
... Washington DC (September23, 2009) SAGE is partnering with the ... in 2010. A peer-reviewed quarterly journal, Cartilage will ... many types of researchers and clinicians involved in cartilage biology ... Cartilage is edited by Roy D. Altman, M.D., ...
... H1N1 influenza could slow growth in key industries and ... of 2009, says a health economist in the University of ... travel are vitally important sectors in the economy of many ... severity of the spread of the virus, consumers and businesses ...
Cached Medicine News:Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 2Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 3Health News:R. Kerry Clark and Robert J. Palmisano Join Bausch & Lomb Board of Directors 2Health News:Society of Interventional Radiology Foundation receives $1 million legacy gift 2Health News:Swine flu could wreak more havoc on US economy, says UAB economist 2